Article

Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors

Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg AöR, Magdeburg, Germany. juri.ruf @ med.ovgu.de
Neuroendocrinology (Impact Factor: 4.93). 12/2009; 91(1):101-9. DOI: 10.1159/000265561
Source: PubMed

ABSTRACT Retrospective evaluation of the impact of integrated positron emission tomography/computed tomography (PET/CT) using (68)Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTATOC) on the therapeutic management of patients with neuroendocrine tumors (NET).
The (68)Ga-DOTATOC-PET/CT data of 66 patients (31 male, 35 female; age: 29-79, mean age: 56 years) with known or suspected NET were included. Imaging data (PET and triple-phase contrast-enhanced CT) were evaluated in consensus by two readers for the visualization of NET manifestations. Combined PET/CT, clinical and imaging follow-up as well as histopathology (if available) served as the reference standard. In order to assess the impact of the respective submodalities on the therapeutic strategy chosen, the results were compared to the treatment decision made by the interdisciplinary NET tumor board of our institution.
Two of the initial 66 patients included did not suffer from NET according to further immunohistopathological examination. In 50 of the remaining 64 (78%) NET patients, a total of 181 NET manifestations were detected by PET/CT. 59/181 (32.6%) were detected by one submodality only (CT 17.1%, PET 15.5%, p for comparison of both = 0.459). Combined PET/CT reading had an impact on the therapeutic management in 24 of 64 (38%) NET patients: primary resection (n = 5), curative lymph node resection (n = 1), initiation/switch of chemotherapy (CTx) due to progressive disease (n = 10), no surgery due to systemic disease (n = 2), radiopeptide receptor therapy instead of CTx (n = 1), additional bisphosphonate therapy (n = 4), and hepatic brachytherapy (n = 1). In 12 of 24 (50%) of these patients, relevant findings were detected by a single submodality only: CT (n = 5), PET (n = 7); p for comparison = 0.774).
(68)Ga-DOTATOC-PET/CT influences therapeutic management in about one third of patients examined. CT and PET are comparably sensitive, deliver complementary information and equally contribute to therapeutic decision-making. Thus, despite the merits of the PET modality, the CT component must not be neglected and an optimized multiphase CT protocol is recommended.

1 Follower
 · 
121 Views
  • Conference Paper: The AFIT VHDL environment
    [Show abstract] [Hide abstract]
    ABSTRACT: An overview is presented of the research into a UNIX-based very high-speed integrated circuit hardware description language (VHDL) toolset at the Air Force Institute of Technology. The toolset supports the new IEEE Standard VHDL (IEEE Std 1076-1987), utilizes standard UNIX utilities, and consists of an analyzer and simulator. A graphical front-end has been designed to run on personal computers. Graphical VHDL User Interface (GVUI) appears to its users as a typical schematic editor. However, logic devices are not labeled with device and pin numbers, but rather with entity names and port labels. This simple labeling transformation repetitively exposes the engineer who is unfamiliar with VHDL to conventional and familiar layout symbology encompassing VHDL terminology and concepts. The GVUI maps what is new-VHDL-to what is already known-schematic layout
    Frontiers in Education Conference, 1988., Proceedings; 11/1988
  • Methods in Enzymology 02/2002; 348:35-42. DOI:10.1016/S0076-6879(02)48623-5 · 2.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ZusammenfassungGastrointestinale neuroendokrine Tumoren sind selten. Sie werden in Abhängigkeit von dem Vorliegen eines Hypersekretionssyndroms als funktionell bzw. nichtfunktionell klassifiziert. Die Diagnose «funktioneller neuroendokriner Tumor» erfordert die klinischen Symptome, die durch eine autonome Hypersekretion von Hormonen oder Neurotransmittern bedingt werden. Diagnostisch stehen klare Richtlinien für die zunächst anzustrebende biochemische/endokrinologische Diagnose zur Verfügung. Erst in einem zweiten Schritt wird dann die Lokalisationsdiagnostik aufgenommen. Der vorliegende Beitrag stellt die biochemische/endokrinologische Diagnostik bei Gastrinom, Insulinom, Karzinoid-Syndrom sowie nichtfunktionellen Tumoren des Pankreas, Jejunums und Ileums ausführlich dar, diskutiert die Differentialdiagnosen und weist auf «Pitfalls» im diagnostischen Vorgehen hin. Für jede Tumorart werden in einem zweiten Schritt die Algorithmen der Lokalisationsdiagnostik dargestellt. Aussagen zur Prognose schließen das jeweilige Tumorkapitel ab.
    Viszeralmedizin / Visceral Medicine 01/2010; 26(4):242-252. DOI:10.1159/000322359 · 0.10 Impact Factor
Show more